long-acting amylin analog · studied for weight loss, appetite control, paired with semaglutide (CagriSema)

Cagrilintide dosage

Cagrilintide is a once-weekly amylin analog from Novo Nordisk, not yet approved. The phase 2 trial in the Lancet tested 0.3 to 4.5 mg weekly for 26 weeks and saw 6% to 10.8% weight loss. In the REDEFINE 1 phase 3 trial it was paired with semaglutide at 2.4 mg each and averaged 20.4% weight loss at 68 weeks. People using research vials usually start at 0.25 to 0.3 mg and climb every 4 weeks toward 2.4 mg, often alongside a GLP-1.

By the Peptide Calculations editors · Updated 2026-10-19

0.3 mg to 4.5 mgper week

Basis: clinical trial (phase 2, Lau et al., Lancet 2021). 0.3, 0.6, 1.2, 2.4 and 4.5 mg arms, escalation over up to 6 weeks, 26 week weight loss 6.0% to 10.8%

How often: once weekly
When: same day each week; if stacked with a GLP-1, most people inject both the same day
How long: continuous while in use; trials ran 26 and 68 weeks
Route: subcutaneous, abdomen or thigh; rotate sites
Storage: lyophilized: fridge or freezer; reconstituted: fridge, commonly used within 4 weeks (commonly reported)

Dose ranges by source

Range	Per	Basis	Note
0.3 mg to 4.5 mg	week	clinical trial (phase 2, Lau et al., Lancet 2021)	0.3, 0.6, 1.2, 2.4 and 4.5 mg arms, escalation over up to 6 weeks, 26 week weight loss 6.0% to 10.8%
2.4 mg	week	clinical trial (phase 3, REDEFINE 1, Garvey et al., NEJM 2025)	2.4 mg cagrilintide plus 2.4 mg semaglutide, escalated every 4 weeks, 68 weeks, mean weight change 20.4%
0.25 mg to 2.4 mg	week	commonly reported	self-reported users start at 0.25 to 0.3 mg and double roughly every 4 weeks; 4.5 mg is rarely used outside the trial

Titration schedule

Step up on this schedule; stay a step longer if side effects are rough.

Weeks	Dose
1-4	0.25 mg to 0.3 mg
5-8	0.6 mg
9-12	1.2 mg
13 onward	2.4 mg

Cagrilintide dose to units chart

5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL (25 mcg per unit on a U-100 insulin syringe). 5 mg + 2 mL = 2.5 mg/mL, so 0.5 mg = 0.2 mL = 20 units; 0.25 mg = 10 units, 1.2 mg = 48 units, 2.4 mg = 96 units. A 10 mg vial with 4 mL gives the same numbers.

Dose	mL	Units (U-100)	Doses per vial
250 mcg	0.1	10	20
300 mcg	0.12	12	16
500 mcg	0.2	20	10
600 mcg	0.24	24	8
1 mg	0.4	40	5
1.2 mg	0.48	48	4
2 mg	0.8	80	2
2.4 mg	0.96	96	2
2.5 mg	1	100	2
4.5 mg	1.8	180	1
5 mg	2	200	1

Different vial or water? Full 5 mg + 2 mL table or set your own numbers below.

Commonly stacked with

Semaglutide 0.25 mg to 2.4 mg
Tirzepatide 2.5 mg to 15 mg
Retatrutide 1 mg to 12 mg

Side effects

nausea
vomiting
constipation
reduced appetite
injection site reactions
fatigue
headache

Before you start. Not approved, so there is no label dose; the numbers are trial arms and self-reports. Pairing it with semaglutide roughly doubled the rate of GI side effects in REDEFINE 1 (about 80% versus 40% on placebo), and a home-made CagriSema stack has no safety data outside those trials. Amylin analogs slow stomach emptying, so go slow with oral medications and alcohol. Not medical advice; start low and talk to a clinician.

Cagrilintide dosage questions

How much cagrilintide should I take?

Trial doses ran 0.3 mg to 4.5 mg once weekly, and the phase 3 combination used 2.4 mg. Self-reported users start at 0.25 to 0.3 mg and double every 4 weeks or so until they reach 2.4 mg. On a 5 mg vial in 2 mL the 0.25 mg start is 10 units.

Can you take cagrilintide with semaglutide?

That pairing is CagriSema, which Novo Nordisk tested at 2.4 mg of each in REDEFINE 1 with 20.4% average weight loss at 68 weeks. In the trial both drugs were titrated together every 4 weeks. Doing it yourself with two vials has no safety data, and GI side effects were about twice as common as placebo.

Cagrilintide vs semaglutide, which is stronger?

Alone, cagrilintide 4.5 mg gave 10.8% weight loss at 26 weeks, about the same as liraglutide 3 mg in the same trial. Semaglutide 2.4 mg alone gives more. The point of cagrilintide is the combination, where it added several percentage points on top of semaglutide.

Is cagrilintide approved?

No. As of this writing it is only available as the investigational half of CagriSema in trials or as research material. There is no FDA label and no official dose.

Sources

Brands we recommend for Cagrilintide. We are independent and have no affiliation with any brand: no affiliate links, no referral codes, no paid placements. These are the suppliers whose testing and certificates hold up when we check them.

Licensed Peptides two accredited labs on every lot, certificates public, card and Apple Pay checkout
Core Peptides long track record, public certificates, wide catalog
Ascension Peptides public third-party testing, clear pricing

This page is an educational summary of published labels, trials and commonly reported use. It is not medical advice and does not replace a clinician.